This is a working overview of GHSR-1a, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-24 and is reviewed periodically as new material appears.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
This would be the driving force behind Morpheus' descent into fanatical terrorism against the system in an attempt to force the machines to reveal Neo's fate; ultimately leading to his assassination. The subject of Neo then fell to the side lines for other struggles; until the arrival of the Oligarchs in Chapter 9. The original intruder, Halborn, was notably intrigued by the life of the One and was personally shocked about the implications of Neo's ability to affect Machines outside of the simulation had on his search for what he called the "Biological Interface Program". After Halborn's removal in Chapter 10, little more was questioned until the revelation of the Trinity project, originally headed by the Oracle, in Chapter 12. It was revealed that both Neo and Trinity were actually the culmination of decades of machine research into translating human DNA perfectly into machine code; allowing them to interface directly with technology without the need for simulated interfaces.
UPMC Community Osteopathic located in Harrisburg, Pennsylvania UPMC West Shore located in Mechanicsburg, Pennsylvania UPMC Somerset, a 111-bed, general acute care community hospital located in Somerset, Pennsylvania UPMC Susquehanna which comprises five hospitals, including its tertiary flagship UPMC Williamsport, operates the additional four community hospitals in north central Pennsylvania and one outpatient emergency center: UPMC Cole located in Coudersport, Pennsylvania. It has 25 beds and its labor and delivery unit is scheduled to close in April 2025. UPMC Lock Haven (outpatient emergency center) located in Lock Haven, Pennsylvania UPMC Muncy located in Muncy, Pennsylvania UPMC Wellsboro located in Wellsboro, Pennsylvania UPMC Williamsport Divine Providence Campus located in Williamsport, Pennsylvania UPMC Washington, a 244-bed hospital located in Washington, Pennsylvania UPMC Greene, a 23-bed hospital of the former Washington Health System located in Waynesburg, Pennsylvania UPMC Western Maryland, a 200-bed hospital located in Cumberland, Maryland
=== Carbonyl protecting groups === The most common protecting groups for carbonyls are acetals and typically cyclic acetals with diols. The runners-up used are also cyclic acetals with 1,2‑hydroxythiols or dithioglycols – the so-called O,S– or S,S-acetals.
== History and etymology == Glycine was discovered in 1820 by French chemist Henri Braconnot when he hydrolyzed gelatin by boiling it with sulfuric acid. He originally called it "sugar of gelatin", but French chemist Jean-Baptiste Boussingault showed in 1838 that it contained nitrogen. In 1847 American scientist Eben Norton Horsford, then a student of the German chemist Justus von Liebig, proposed the name "glycocoll"; however, the Swedish chemist Berzelius suggested the simpler current name a year later. The name comes from the Greek word γλυκύς "sweet tasting" (which is also related to the prefixes glyco- and gluco-, as in glycoprotein and glucose). In 1858, the French chemist Auguste Cahours determined that glycine was an amine of acetic acid.
==== Absorption ==== Propranolol is rapidly and completely absorbed, with peak plasma levels achieved about 2 hours (range 1–3 hours) after ingestion. Its oral bioavailability is approximately 25%. Despite complete absorption, propranolol has a variable bioavailability due to extensive first-pass metabolism. Hepatic impairment therefore increases its bioavailability. Therapeutic plasma concentrations are typically between 0.02 and 0.3 mg/L. Toxicity has been reported at concentrations of 1 mg/L and above, with coma or death associated with concentrations of 4 to 10 mg/L and above. Coadministration with food appears to enhance bioavailability but does not hasten its time to peak levels. Propranolol can be absorbed along the whole intestine with the main absorption site being the colon, which means people who have lost their colon due to surgery may absorb less propranolol. Propranolol shows marked interindividual variability in pharmacokinetics, with propranolol levels varying 20-fold in different individuals.
Sources: en.wikipedia.org
Duterte signed the Paris Agreement on Climate Change in March 2017, after initially having misgivings about the deal which he says might limit the country's industrialization. The Agreement was ratified by the Senate on March 15, 2017. Duterte said that rich countries producing the most carbon emissions must pay smaller countries for damage caused by climate change.
[We] have to act according not only to the facts but to the ... evidence. I am sure you understand that these are very grave accusations." The European Ombudsman, Emily O'Reilly, was, however critical of the response of Von der Leyen and fellow politicians and institutions, highlighting the lack of progress shown by von der Leyen following her pledge that transparency would be a core part of her mandate when she became European Commission President. O'Reilly called for a body to be created with real investigatory and sanctions powers. The Belgian Prime Minister, Alexander De Croo, was also critical of the European institutions in his response, stating that "Belgian justice is doing what, at first sight, the European Parliament hasn't done." "The European Parliament has a lot of means to regulate itself. It turns out that this is largely a system of auto-control based on voluntary efforts, which has clearly not been sufficient." Annalena Baerbock, the German Minister for Foreign Affairs, highlighted that the scandal is leading to concerns from citizens and affects the credibility and legitimacy of the institutions of the European Union. On 15 December the European People's Party (EPP) reacted by declaring, "We need to discuss hypocrisy ... This is an S&D scandal." In an attempt to focus the scandal on the Progressive Alliance of Socialists and Democrats Group (S&D), rather than the European Parliament as a whole, they continued, "There has been a consistent effort to turn #Qatargate into an institutional issue alone. But this scandal is not an orphan. ... It has an address.
== Release and commercial performance == Upon its release in September 1992, Dirt peaked at number six on the Billboard 200 and charted for 102 weeks, ending at number 196 in the week of September 24, 1994. Dirt granted Alice in Chains international recognition, and the album was certified 5× platinum in the United States, platinum in Canada and gold in the UK. The album had sold 3,358,000 copies in the United States as of 2008. It is the band's most commercially successful album. A remastered reissue of the album was released on vinyl on November 23, 2009. Dirt included the top-30 singles "Would?", "Them Bones", "Angry Chair", "Rooster", and "Down in a Hole", all of which had accompanying music videos. The album returned to the top 10 of the Billboard 200 chart at No. 9 following the release of its 30th anniversary reissue on September 23, 2022.
As it affects glycogenolysis, it has been suggested that it should re-designated as GSD-XIV. Lafora disease is considered a complex neurodegenerative disease and also a glycogen metabolism disorder. Polyglucosan storage myopathies are associated with defective glycogen metabolism (Not McArdle disease, same gene but different symptoms) Myophosphorylase-a activity impaired: Autosomal dominant mutation on PYGM gene. AMP-independent myophosphorylase activity impaired, whereas the AMP-dependent activity was preserved. No exercise intolerance. Adult-onset muscle weakness. Accumulation of the intermediate filament desmin in the myofibers of the patients. Myophosphorylase comes in two forms: form 'a' is phosphorylated by phosphorylase kinase, form 'b' is not phosphorylated. Both forms have two conformational states: active (R or relaxed) and inactive (T or tense). When either form 'a' or 'b' are in the active state, then the enzyme converts glycogen into glucose-1-phosphate. Myophosphorylase-b is allosterically activated by AMP being in larger concentration than ATP and/or glucose-6-phosphate. (See Glycogen phosphorylase§Regulation). Unknown glycogenosis related to dystrophy gene deletion: patient has a previously undescribed myopathy associated with both Becker muscular dystrophy and a glycogen storage disorder of unknown aetiology.
Measurements over 10 pCi/L warrant only another short-term test so that abatement measures are not unduly delayed. The EPA has advised purchasers of real estate to delay or decline a purchase if the seller has not successfully abated radon to 4 pCi/L or less. Because the half-life of radon is only 3.8 days, removing or isolating the source will greatly reduce the hazard within a few weeks. Another method of reducing radon levels is to modify the building's ventilation. Generally, the indoor radon concentrations increase as ventilation rates decrease. In a well-ventilated place, the radon concentration tends to align with outdoor values (typically 10 Bq/m3 (0.27 pCi/L), ranging from 1 to 100 Bq/m3 (0.027 to 2.703 pCi/L). The four principal ways of reducing the amount of radon accumulating in a house are:
Sources: en.wikipedia.org
For given RTD, there is an upper limit on the amount of mixing that can occur, called the maximum mixedness, and this determines the achievable yield. A continuous stirred-tank reactor can be anywhere in the spectrum between completely segregated and perfect mixing. The RTD of chemical reactors can be obtained by CFD simulations. The very same procedure that is performed in experiments can be followed. A pulse of inert tracer particles (during a very short time) is injected into the reactor. The linear motion of tracer particles is governed by Newton's second law of motion and a one-way coupling is stablished between fluid and tracers. In one-way coupling, fluid affects tracer motion by drag force while tracer does not affect fluid. The size and density of tracers are chosen so small that the time constant of tracers becomes very small. In this way, tracer particles exactly follow the same path as the fluid does.
== Origins == Gluconeogenesis is considered one of the most ancient anabolic pathways and is likely to have been exhibited in the last universal common ancestor. Rafael F. Say and Georg Fuchs stated in 2010 that "all archaeal groups as well as the deeply branching bacterial lineages contain a bifunctional fructose 1,6-bisphosphate (FBP) aldolase/phosphatase with both FBP aldolase and FBP phosphatase activity. This enzyme is missing in most other Bacteria and in Eukaryota, and is heat-stabile even in mesophilic marine Crenarchaeota". It is proposed that fructose 1,6-bisphosphate aldolase/phosphatase was an ancestral gluconeogenic enzyme and had preceded glycolysis. However, a prebiotic glycolysis would follow the same chemical mechanisms as gluconeogenesis, due to microscopic reversibility, and in this view would have occurred at the same time. Fructose 1,6-bisphosphate is shown to be nonenzymatically synthesized within a freezing solution. The synthesis is accelerated in the presence of amino acids such as glycine and lysine. Some of the other reactions of gluconeogenesis can also proceed nonenzymatically. Such chemistry could have occurred in hydrothermal environments, including temperature gradients and cycling of freezing and thawing. Mineral surfaces might have played a role in the phosphorylation of metabolic intermediates from gluconeogenesis and have been shown to produce tetrose, hexose phosphates, and pentose from formaldehyde, glyceraldehyde, and glycolaldehyde.
== Synthesis == The compound was first described in 1935 by Ferdinand Münz, who prepared the compound from ethylenediamine and chloroacetic acid. Today, EDTA is mainly synthesised from ethylenediamine (1,2-diaminoethane), formaldehyde, and sodium cyanide. This route yields the tetrasodium EDTA, which is converted in a subsequent step into the acid forms:
=== Replacement therapy === GH is used as replacement therapy in adults with GH deficiency of either childhood-onset or adult-onset (usually as a result of an acquired pituitary tumor). In these patients, benefits have variably included reduced fat mass, increased lean mass, increased bone density, improved lipid profile, reduced cardiovascular risk factors, and improved psychosocial well-being. Long acting growth hormone (LAGH) analogues are now available for treating growth hormone deficiency both in children and adults. These are once weekly injections as compared to conventional growth hormone which has to be taken as daily injections. LAGH injection 4 times a month has been found to be as safe and effective as daily growth hormone injections.
The common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating. Bupropion has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine. It is also associated with about 20% increased risk of headache. Bupropion raises blood pressure in some people. One study showed an average rise of 6 mm Hg in systolic blood pressure in 10% of patients. The prescribing information notes that hypertension, sometimes severe, is observed in some people taking bupropion, both with and without pre-existing hypertension. The safety of bupropion in people with cardiovascular conditions and its general cardiovascular safety profile remains unclear due to the lack of data. Bupropion has not been associated with QT prolongation at therapeutic doses but has been associated with QT prolongation in overdose. Seizure is a rare but serious adverse effect of bupropion. It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at 300 to 450 mg per day; the incidence climbs almost 10-fold for the higher-than-recommended dose of 600 mg. For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally 0 to 0.5% at the recommended doses. Rare cases of liver toxicity leading to death or liver transplantation have been reported for bupropion.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.